Fmr LLC Savara Inc Transaction History

Fmr LLC

$1.68 Trillion
Q2 2025

A detailed history of Fmr LLC transactions in Savara Inc stock. As of the latest transaction made, Fmr LLC holds 5,651 shares of SVRA stock, worth $21,021. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,651

Previous 13,082 56.8%

Holding current value

$21,021

Previous $36,000 66.67%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$1.99 - $3.4 $14,787 - $25,265	-7,431 Reduced 56.8%	5,651 $12,000
Q1 2025 May 12, 2025	SELL	$2.32 - $3.14 $2.41 Million - $3.27 Million	-1,040,426 Reduced 98.76%	13,082 $36,000
Q4 2024 Feb 13, 2025	SELL	$2.94 - $4.07 $89,331 - $123,666	-30,385 Reduced 2.8%	1,053,508 $3.23 Million
Q3 2024 Nov 13, 2024	BUY	$3.96 - $5.07 $376,809 - $482,430	95,154 Added 9.62%	1,083,893 $4.6 Million
Q2 2024 Aug 13, 2024	BUY	$3.66 - $5.34 $3.61 Million - $5.27 Million	986,724 Added 48968.93%	988,739 $3.98 Million
Q1 2024 May 13, 2024	SELL	$4.19 - $5.59 $1,202 - $1,604	-287 Reduced 12.47%	2,015 $10,000
Q4 2023 Feb 13, 2024	SELL	$3.18 - $4.9 $5,530 - $8,521	-1,739 Reduced 43.03%	2,302 $10,000
Q3 2023 Nov 13, 2023	BUY	$2.97 - $3.88 $6,403 - $8,365	2,156 Added 114.38%	4,041 $15,000
Q2 2023 Aug 11, 2023	BUY	$1.69 - $3.24 $197 - $379	117 Added 6.62%	1,885 $6,000
Q1 2023 May 11, 2023	BUY	$1.6 - $2.82 $153 - $270	96 Added 5.74%	1,768 $3,000
Q2 2022 Aug 12, 2022	SELL	$1.1 - $1.58 $83 - $120	-76 Reduced 4.35%	1,672 $3,000
Q1 2022 May 13, 2022	BUY	$1.05 - $1.36 $1,835 - $2,377	1,748 New	1,748 $2,000
Q4 2021 Feb 14, 2022	SELL	$1.04 - $1.34 $2,080 - $2,680	-2,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$1.18 - $1.64 $2,358 - $3,278	1,999 Added 199900.0%	2,000 $2,000
Q2 2021 Aug 13, 2021	BUY	$1.51 - $2.29 $1 - $2	1 New	1 $0

Others Institutions Holding SVRA

# of Institutions

129

Shares Held

167M

Call Options Held

38.7K

Put Options Held

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $424M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account